SEATTLE, WA, July 24, 2013 — LifeSpan BioSciences, Inc. (LSBio), a leading provider of antibodies for researchers worldwide, has increased the number of validated IHC-plusTM antibodies available in its catalog to more than 10,000. With this increase, LSBio is well on its way to its goal of building the world’s largest catalog of 20,000 well characterized, IHC-validated reagent antibodies. Overall, LSBio has a catalog of more than 129,000 antibodies validated for use in many types of assays.
IHC-plusTM antibodies, LSBio’s flagship product line, consists of antibodies that LSBio has validated for use in IHC, drawing on its 17-year track record in designing, manufacturing and using antibodies for immunohistochemistry (IHC). These antibodies have been extensively tested against formalin-fixed paraffin-embedded (FFPE) human tissues. Each antibody has been characterized at four different concentrations against 22 normal human tissues, plus additional controls. These antibodies have been identified as the best reagents for use in FFPE-IHC.
Immunohistochemistry is widely used to visualize proteins (and other antigens) in tissues, and can detect any protein encoded by the 21,000 genes in the human genome. In addition, IHC can detect functionally important protein modifications (such as phosphorylation). To visualize an antibody-antigen interaction with IHC, tissue specimens are fixed in formalin and embedded in wax, and thin sections are placed on microscope slides. After incubation with an antibody, the bound antibody is stained with a dye, and the slides are examined under a microscope by a pathologist to detect specific molecular markers. All of LSBio’s IHC-plusTM antibodies are documented with high resolution images of stained tissues, which are of great value to researchers in evaluating antibody specificity and their suitability for their own studies.
“Our 17-year history in delivering IHC services and validating antibodies makes LSBio uniquely qualified to meet the need for high-quality, IHC-validated antibodies to thousands of new protein targets,” said Glenna Burmer, M.D., Ph.D., chief scientific officer and executive vice president. “LifeSpan is rapidly becoming the market leader for these important antibody reagents.”
LSBio has grown its antibody business exponentially over the past five years, and thousands of researchers in more than 50 countries across Europe, Asia and North America now rely on LifeSpan BioSciences for their antibodies.
“With our rapidly expanding product line, our reagent antibody revenues have increased rapidly over the past few years and we expect them to continue to do so,” said LifeSpan’s CEO, Joe Brown, Ph.D. “In 2013, we are continuing to aggressively expand our antibody catalog of IHC-plusTM antibodies to create value for our customers and strategic partners, and to strengthen our business for the future.”
About LifeSpan BioSciences, Inc.
LifeSpan BioSciences is the industry leader in providing immunohistochemistry services and IHC-validated reagent antibodies to researchers in the pharmaceutical and biotech industries as well as in academia and other research organizations worldwide. Founded in 1995, LSBio has built a catalog of more than 129,000 reagent antibodies, including more than 10,000 IHC-plusTM antibodies. LSBio sells reagent antibodies from its online catalog as well as through an expanding network of international distributors. www.lsbio.com/.